124 related articles for article (PubMed ID: 35780816)
21. Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China.
Liu Q; Luo X; Peng L; Yi L; Wan X; Zeng X; Tan C
BMJ Open; 2020 Nov; 10(11):e040691. PubMed ID: 33243806
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients.
Li WQ; Li LY; Chai J; Cui JW
Cancer Med; 2021 Mar; 10(6):1964-1974. PubMed ID: 33626238
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of a 14-gene risk score assay to target adjuvant chemotherapy in early stage non-squamous non-small cell lung cancer.
Roth JA; Billings P; Ramsey SD; Dumanois R; Carlson JJ
Oncologist; 2014 May; 19(5):466-76. PubMed ID: 24710309
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of stereotactic body radiotherapy and surgery for medically operable early stage non small cell lung cancer.
Paix A; Noel G; Falcoz PE; Levy P
Radiother Oncol; 2018 Sep; 128(3):534-540. PubMed ID: 29706462
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Grossi F; Costa F
Clin Ther; 2020 May; 42(5):830-847. PubMed ID: 32354495
[TBL] [Abstract][Full Text] [Related]
27. A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC).
Panje CM; Dedes KJ; Matter-Walstra K; Schwenkglenks M; Gautschi O; Siano M; Aebersold DM; Plasswilm L; Lupatsch JE;
Radiother Oncol; 2018 Nov; 129(2):257-263. PubMed ID: 30104008
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
Courtney PT; Yip AT; Cherry DR; Salans MA; Kumar A; Murphy JD
JAMA Netw Open; 2021 May; 4(5):e218787. PubMed ID: 33938936
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore.
Aziz MIA; Foo WYX; Toh CK; Lim WT; Ng K
J Med Econ; 2020 Nov; 23(11):1330-1339. PubMed ID: 32886557
[TBL] [Abstract][Full Text] [Related]
30. A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland.
Barbier MC; Pardo E; Panje CM; Gautschi O; Lupatsch JE;
Eur J Health Econ; 2021 Jul; 22(5):669-677. PubMed ID: 33745093
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Polyzoi M; Sandhu H; Maervoet J; Yuan Y; Chaudhary MA; Varol N; Lee A; Dale P; Jones C; Lubinga SJ; Penrod JR
J Med Econ; 2022; 25(1):660-668. PubMed ID: 35658806
[TBL] [Abstract][Full Text] [Related]
32. Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA.
Ionova Y; Vuong W; Sandoval O; Fong J; Vu V; Zhong L; Wilson L
Clin Drug Investig; 2022 Jun; 42(6):491-500. PubMed ID: 35604530
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis of pegfilgrastim in patients with non-small cell lung cancer receiving ramucirumab plus docetaxel in Japan.
Kondo Y; Tachi T; Sakakibara T; Kato J; Kato A; Mizuno T; Miyake Y; Teramachi H
Support Care Cancer; 2022 Aug; 30(8):6775-6783. PubMed ID: 35524869
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer.
Sher DJ; Wee JO; Punglia RS
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e767-74. PubMed ID: 21300476
[TBL] [Abstract][Full Text] [Related]
35. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
[TBL] [Abstract][Full Text] [Related]
36. Impact of video-assisted thoracoscopic lobectomy versus open lobectomy for lung cancer on recovery assessed using self-reported physical function: VIOLET RCT.
Lim E; Harris RA; McKeon HE; Batchelor TJ; Dunning J; Shackcloth M; Anikin V; Naidu B; Belcher E; Loubani M; Zamvar V; Dabner L; Brush T; Stokes EA; Wordsworth S; Paramasivan S; Realpe A; Elliott D; Blazeby J; Rogers CA
Health Technol Assess; 2022 Dec; 26(48):1-162. PubMed ID: 36524582
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of immune checkpoint inhibitors in the treatment of non-small-cell lung cancer as a second line in Taiwan.
Leung JH; Chang CW; Chan AL; Lang HC
Future Oncol; 2022 Mar; 18(7):859-870. PubMed ID: 35105168
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of sugemalimab in combination with chemotherapy as first-line treatment in Chinese patients with metastatic NSCLC.
Chen P; Li Y; Jing X; Chen J; Chen S; Yang Q
Lung Cancer; 2022 Dec; 174():157-164. PubMed ID: 36413882
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China.
Liao W; Huang J; Hutton D; Li Q
J Med Econ; 2019 Apr; 22(4):344-349. PubMed ID: 30646794
[TBL] [Abstract][Full Text] [Related]
40. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]